Log in

NASDAQ:AMGNAmgen Competitors & Alternatives

$249.04
-2.62 (-1.04 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$247.07
Now: $249.04
$251.57
50-Day Range
$217.90
MA: $232.68
$258.24
52-Week Range
$173.12
Now: $249.04
$264.97
Volume1.33 million shs
Average Volume2.65 million shs
Market Capitalization$146.50 billion
P/E Ratio19.52
Dividend Yield2.57%
Beta0.94

Competitors

Amgen (NASDAQ:AMGN) Vs. GILD, CELG, VRTX, REGN, BIIB, and SGEN

Should you be buying AMGN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Amgen, including Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seattle Genetics (SGEN).

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Dividends

Gilead Sciences pays an annual dividend of $2.72 per share and has a dividend yield of 3.6%. Amgen pays an annual dividend of $6.40 per share and has a dividend yield of 2.6%. Gilead Sciences pays out 44.3% of its earnings in the form of a dividend. Amgen pays out 43.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 4 consecutive years and Amgen has increased its dividend for 9 consecutive years.

Profitability

This table compares Gilead Sciences and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences21.84%35.44%12.84%
Amgen32.03%90.75%15.44%

Valuation & Earnings

This table compares Gilead Sciences and Amgen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion4.26$5.39 billion$6.1412.43
Amgen$23.36 billion6.27$7.84 billion$14.8216.80

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Gilead Sciences and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences3151002.25
Amgen1111602.54

Gilead Sciences presently has a consensus price target of $79.6538, suggesting a potential upside of 4.37%. Amgen has a consensus price target of $246.08, suggesting a potential downside of 1.19%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Amgen.

Institutional & Insider Ownership

78.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 75.7% of Amgen shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Gilead Sciences has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Summary

Amgen beats Gilead Sciences on 13 of the 17 factors compared between the two stocks.

Celgene (NASDAQ:CELG) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Celgene and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celgene06002.00
Amgen1111602.54

Celgene presently has a consensus price target of $105.60, suggesting a potential downside of 2.44%. Amgen has a consensus price target of $246.08, suggesting a potential downside of 1.19%. Given Amgen's stronger consensus rating and higher possible upside, analysts clearly believe Amgen is more favorable than Celgene.

Insider and Institutional Ownership

71.7% of Celgene shares are owned by institutional investors. Comparatively, 75.7% of Amgen shares are owned by institutional investors. 0.4% of Celgene shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Celgene and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celgene34.63%78.15%18.54%
Amgen32.03%90.75%15.44%

Valuation and Earnings

This table compares Celgene and Amgen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celgene$15.28 billion5.04$4.05 billion$7.6114.22
Amgen$23.36 billion6.27$7.84 billion$14.8216.80

Amgen has higher revenue and earnings than Celgene. Celgene is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Celgene has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Summary

Amgen beats Celgene on 10 of the 14 factors compared between the two stocks.

Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Amgen and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1111602.54
Vertex Pharmaceuticals082012.76

Amgen presently has a consensus target price of $246.08, suggesting a potential downside of 1.19%. Vertex Pharmaceuticals has a consensus target price of $285.1154, suggesting a potential downside of 3.17%. Given Amgen's higher possible upside, equities analysts plainly believe Amgen is more favorable than Vertex Pharmaceuticals.

Insider & Institutional Ownership

75.7% of Amgen shares are held by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Amgen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen32.03%90.75%15.44%
Vertex Pharmaceuticals31.35%25.69%18.50%

Earnings & Valuation

This table compares Amgen and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.27$7.84 billion$14.8216.80
Vertex Pharmaceuticals$4.16 billion18.34$1.18 billion$4.2968.64

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Amgen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Amgen on 8 of the 14 factors compared between the two stocks.

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Amgen and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1111602.54
Regeneron Pharmaceuticals0121412.59

Amgen presently has a consensus target price of $246.08, suggesting a potential downside of 1.19%. Regeneron Pharmaceuticals has a consensus target price of $573.2593, suggesting a potential downside of 7.67%. Given Amgen's higher possible upside, equities analysts plainly believe Amgen is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Amgen and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen32.03%90.75%15.44%
Regeneron Pharmaceuticals28.56%24.94%18.81%

Earnings & Valuation

This table compares Amgen and Regeneron Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.27$7.84 billion$14.8216.80
Regeneron Pharmaceuticals$7.86 billion8.69$2.12 billion$21.4728.92

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

75.7% of Amgen shares are held by institutional investors. Comparatively, 68.1% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Amgen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Summary

Amgen beats Regeneron Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Amgen and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1111602.54
Biogen517902.13

Amgen currently has a consensus target price of $246.08, suggesting a potential downside of 1.19%. Biogen has a consensus target price of $309.6296, suggesting a potential upside of 11.03%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Amgen.

Profitability

This table compares Amgen and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen32.03%90.75%15.44%
Biogen40.76%49.22%24.26%

Earnings and Valuation

This table compares Amgen and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.27$7.84 billion$14.8216.80
Biogen$14.38 billion3.17$5.89 billion$33.578.31

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.7% of Amgen shares are held by institutional investors. Comparatively, 87.3% of Biogen shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Amgen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Summary

Amgen beats Biogen on 8 of the 14 factors compared between the two stocks.

Amgen (NASDAQ:AMGN) and Seattle Genetics (NASDAQ:SGEN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Amgen and Seattle Genetics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1111602.54
Seattle Genetics171212.62

Amgen currently has a consensus target price of $246.08, suggesting a potential downside of 1.19%. Seattle Genetics has a consensus target price of $148.2778, suggesting a potential downside of 14.95%. Given Amgen's higher possible upside, research analysts plainly believe Amgen is more favorable than Seattle Genetics.

Profitability

This table compares Amgen and Seattle Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen32.03%90.75%15.44%
Seattle Genetics-32.81%-16.51%-13.88%

Earnings and Valuation

This table compares Amgen and Seattle Genetics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.27$7.84 billion$14.8216.80
Seattle Genetics$916.71 million32.92$-158,650,000.00($1.33)-131.09

Amgen has higher revenue and earnings than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.7% of Amgen shares are held by institutional investors. Comparatively, 94.6% of Seattle Genetics shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 31.1% of Seattle Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Amgen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Seattle Genetics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Summary

Amgen beats Seattle Genetics on 9 of the 15 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Gilead Sciences logo
GILD
Gilead Sciences
2.0$76.32-2.1%$95.73 billion$22.45 billion19.62Analyst Revision
Celgene logo
CELG
Celgene
1.7$108.24-0.0%$77.04 billion$15.28 billion14.22
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
1.4$294.45-0.3%$76.34 billion$4.16 billion51.03
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
1.4$620.86-3.2%$68.31 billion$7.86 billion31.20
Biogen logo
BIIB
Biogen
1.9$278.88-0.1%$45.51 billion$14.38 billion8.61Analyst Report
Seattle Genetics logo
SGEN
Seattle Genetics
1.3$174.35-3.9%$30.18 billion$916.71 million-92.74Insider Selling
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.3$108.82-0.3%$24.03 billion$4.99 billion10.25Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.7$126.06-0.6%$22.80 billion$1.70 billion206.66
Incyte logo
INCY
Incyte
1.4$104.76-3.0%$22.77 billion$2.16 billion-59.86Analyst Upgrade
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.5$162.25-2.2%$18.72 billion$219.75 million-20.21Insider Selling
EXACT Sciences logo
EXAS
EXACT Sciences
1.6$92.08-0.7%$13.80 billion$876.29 million-118.05Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
1.8$129.69-1.4%$12.04 billion$788.10 million70.48Insider Selling
Immunomedics logo
IMMU
Immunomedics
1.9$41.32-2.4%$9.54 billion$290,000.00-22.58Analyst Upgrade
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$62.09-2.7%$8.65 billion$1.12 billion56.45
Exelixis logo
EXEL
Exelixis
1.8$24.94-3.0%$7.65 billion$967.78 million26.82Unusual Options Activity
Repligen logo
RGEN
Repligen
1.2$126.13-2.0%$6.60 billion$270.24 million280.30
Novavax logo
NVAX
Novavax
1.5$94.36-2.1%$5.47 billion$18.66 million-22.79Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$117.44-0.4%$5.17 billion$1.45 billion9.79
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.4$94.23-0.3%$4.94 billion$1.11 billion72.49
Momenta Pharmaceuticals logo
MNTA
Momenta Pharmaceuticals
1.6$34.30-2.0%$4.04 billion$23.87 million-12.25
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.53-1.9%$4.00 billion$182.24 million-11.95
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.6$27.90-0.3%$3.79 billion$195.99 million-50.73
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$59.70-1.0%$3.69 billion$36.13 million-54.77
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$65.92-0.3%$3.32 billion$806.43 million-10.20
Alkermes logo
ALKS
Alkermes
1.1$19.69-1.8%$3.13 billion$1.17 billion-22.38
Opko Health logo
OPK
Opko Health
1.7$4.02-0.0%$2.69 billion$901.90 million-8.38
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$115.06-2.5%$1.85 billion$120.28 million-33.45
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$103.91-3.6%$1.60 billionN/A-15.26
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$9.86-0.0%$1.57 billion$428.41 million18.60Heavy News Reporting
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.2$10.69-1.9%$1.51 billion$102.43 million-12.88Analyst Upgrade
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$45.09-2.7%$1.49 billion$252 million-4.21
Innoviva logo
INVA
Innoviva
0.9$13.46-0.9%$1.36 billion$261.02 million7.87Analyst Downgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$5.44-1.7%$958.74 million$48.83 million-5.79Analyst Upgrade
Myriad Genetics logo
MYGN
Myriad Genetics
1.4$11.47-0.3%$855.14 million$851.10 million-5.74
Dynavax Technologies logo
DVAX
Dynavax Technologies
2.1$8.66-5.9%$798.31 million$35.22 million-4.71Analyst Report
ImmunoGen logo
IMGN
ImmunoGen
1.4$4.32-11.3%$753.43 million$82.27 million-7.45
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.6$3.37-3.6%$722.14 million$150,000.00-4.81Analyst Report
Codexis logo
CDXS
Codexis
1.5$11.46-3.8%$676.35 million$68.46 million-45.84
Agenus logo
AGEN
Agenus
1.5$3.79-3.4%$634.39 million$150.05 million-3.06
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
2.0$11.49-0.9%$626.78 million$227.19 million5.37
Molecular Templates logo
MTEM
Molecular Templates
1.6$12.93-0.9%$591.29 million$22.27 million-5.96
Clovis Oncology logo
CLVS
Clovis Oncology
1.7$6.62-1.2%$509.08 million$143.01 million-0.92
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.9$63.21-1.3%$464.27 million$38.19 million18.98
Geron logo
GERN
Geron
1.2$2.15-0.5%$437.13 million$460,000.00-5.51
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.34-0.9%$389.01 million$109.33 million-2.78Analyst Downgrade
MannKind logo
MNKD
MannKind
1.9$1.78-1.1%$379.39 million$63.04 million-7.74
Progenics Pharmaceuticals logo
PGNX
Progenics Pharmaceuticals
1.5$4.10-0.0%$355.05 million$34.99 million-5.32High Trading Volume
PDL BioPharma logo
PDLI
PDL BioPharma
1.0$2.81-0.7%$319.61 million$54.76 million-2.99
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.5$1.78-2.2%$300.05 million$59.29 million-11.13
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.9$11.55-7.4%$260.51 million$3.57 million-3.90
This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.